We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+13.35%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.41B
AUM Growth
-$85.8M
(-3.4%)
Cap. Flow
-$78.4M
Cap. Flow
% of AUM
-3.25%
Top 10 Holdings %
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
+$65M |
| 2 |
Pliant Therapeutics
PLRX
|
+$15.3M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$12.4M |
| 4 |
Trevi Therapeutics
TRVI
|
+$10.5M |
| 5 |
PVLA
Palvella Therapeutics
PVLA
|
+$10M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
+$49.7M |
| 2 |
Krystal Biotech
KRYS
|
+$35.5M |
| 3 |
Vaxcyte
PCVX
|
+$33.8M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$30.2M |
| 5 |
Tyra Biosciences
TYRA
|
+$17.2M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NewAmsterdam Pharma
NAMS
$3.63B
| $409M | 16.98% |
15,916,418
+3,061,224
| +24% | +$65M |
|
2
Mirum Pharmaceuticals
MIRM
$7.16B
| $272M | 11.28% |
6,570,392
| – | – |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $157M | 6.52% |
3,383,950
| – | – |
|
|
4
Krystal Biotech
KRYS
$10.1B
| $124M | 5.13% |
788,460
-200,000
| -20% | -$35.5M |
|
5
Arcutis Biotherapeutics
ARQT
$3.47B
| $122M | 5.08% |
8,785,284
| – | – |
|
6
Disc Medicine
IRON
$2.81B
| $111M | 4.62% |
1,754,834
| – | – |
|
|
MBX
7
MBX Biosciences
MBX
$2.78B
| $110M | 4.58% |
5,985,347
| – | – |
|
|
8
Rhythm Pharmaceuticals
RYTM
$7.28B
| $105M | 4.34% |
1,869,808
-547,144
| -23% | -$30.2M |
|
9
BridgeBio Pharma
BBIO
$15.7B
| $104M | 4.33% |
3,800,457
+40,000
| +1% | +$1.03M |
|
10
Tarsus Pharmaceuticals
TARS
$2.52B
| $87.9M | 3.65% |
1,587,527
| – | – |
|
11
Phathom Pharmaceuticals
PHAT
$875M
| $82.1M | 3.41% |
10,109,279
| – | – |
|
12
Erasca
ERAS
$5.91B
| $48.7M | 2.02% |
19,391,687
| – | – |
|
|
13
Vaxcyte
PCVX
$8.09B
| $44.2M | 1.83% |
539,405
-340,000
| -39% | -$33.8M |
|
|
14
Trevi Therapeutics
TRVI
$2.46B
| $43.9M | 1.82% |
10,664,774
+3,283,684
| +44% | +$10.5M |
|
15
Revolution Medicines
RVMD
$38.1B
| $43.6M | 1.81% |
997,455
| – | – |
|
|
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
| $41.4M | 1.72% |
4,887,867
+1,200,000
| +33% | +$12.4M |
|
17
Agios Pharmaceuticals
AGIO
$2.3B
| $35.2M | 1.46% |
1,069,754
+25,600
| +2% | +$1.2M |
|
|
18
Edgewise Therapeutics
EWTX
$4.11B
| $33.9M | 1.41% |
1,271,245
-1,561,622
| -55% | -$49.7M |
|
|
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
| $31.4M | 1.3% |
699,159
-176,508
| -20% | -$9.15M |
|
20
Oric Pharmaceuticals
ORIC
$1.11B
| $31.4M | 1.3% |
3,888,238
-254,617
| -6% | -$2.34M |
|
21
Ultragenyx Pharmaceutical
RARE
$2.98B
| $27.7M | 1.15% |
658,715
+25,000
| +4% | +$1.24M |
|
22
Savara
SVRA
$1.13B
| $26.6M | 1.1% |
8,660,379
+502,994
| +6% | +$1.75M |
|
23
CG Oncology
CGON
$6.13B
| $22.1M | 0.92% |
770,000
| – | – |
|
|
HLVX
24
DELISTED
HilleVax
HLVX
| $22M | 0.91% |
10,617,062
| – | – |
|
25
AnaptysBio
ANAB
$1.6B
| $20.8M | 0.86% |
1,573,719
-635,470
| -29% | -$15.4M |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG